Dernières nouvelles pour Nebius Group (NASDAQ:NBIS) Stock

Nebius Group

Nebius Group N.V. - Class A Ordinary Shares

Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&D hubs across Europe, North America and Israel.

Nebius Group NV

Canaccord Genuity analyst Brian McNamara maintains Worthington Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) with a Buy and raises the price target from $69 to $81.

News

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Worthington Enterprises, Raises Price Target to $81

Canaccord Genuity analyst Austin Moeller maintains BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) with a Buy and raises the price target from $14 to $20.

BlackSky Technology Inc. Class A Common Stock

BKSY

Canaccord Genuity Maintains Buy on BlackSky Technology, Raises Price Target to $20

Ocean Power Technologies, Inc. (OPT or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>), a leader in innovative and sustainable marine energy and data solutions, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. patent application titled "System and Method for Vehicle Charging."
The newly allowed patent (Application No. 18/936,528) protects OPT's breakthrough system for an autonomous, floating marine charging solution. Designed to address the increasing demand for clean maritime operations, the invention enables electric vessels—including uncrewed surface vehicles—to safely locate, dock with, and recharge from a floating energy platform while at sea.

OPTT

Ocean Power Technologies Secures U.S. Patent For "System And Method For Vehicle Charging"

A Harvard scholar has suggested that the United States and China are on the verge of finalizing a trade deal, with the potential for an&nbsp;agreement as soon as next&nbsp;week.
What Happened:  Graham Allison, the founding dean of Harvard University&#8216;s John F. Kennedy School of Government and a former U.S. official, hinted at the possibility of a trade deal between the U.S. and China. He made these remarks at a World Economic Forum (WEF) meeting in Tianjin on Thursday, <a href="https://www.scmp.com/news/china/diplomacy/article/3315914/us-china-trade-deal-near-harvard-scholar-hints-progress-very-intense-talks?module=top_story&amp;pgtype=homepage">reported</a> the South China Morning Post.
Allison stated, &nbsp;&#8220;I&nbsp;would be surprised if in&nbsp;the next week or so&nbsp;we do not see an&nbsp;MOU (memorandum of understanding) coming&nbsp;out of the discussions that&nbsp;have been going on between&nbsp;Bessent and He and their&nbsp;teams in the intermediate period,&#8221; referring to U.S. Treasury Secretary&nbsp;Scott Bessent&nbsp;and China's Vice-Premier&nbsp;He Lifeng, who are leading the trade talks.
Allison shared his perspective on the trade talks following a recent meeting with China's top diplomat, Wang Yi, who voiced optimism about achieving peaceful coexistence between the two countries.
"These are business problems that serious businesspeople know how to solve. And I'm thinking they are going to stabilize this, I believe. But we'll see,"&nbsp;stated Allison
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/equities/25/06/46107333/nvidia-micron-technology-super-micro-computer-bp-and-tesla-why-these-5-stocks-are-on-investors-r" target="_blank" rel="noreferrer noopener">Nvidia, Micron Technology, Super Micro Computer, BP And Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a>
Why It Matters: The ongoing trade war between the US and China has had significant impacts on both economies. U.S.-listed Chinese stocks such as&nbsp;Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>),&nbsp;Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), and&nbsp;JD.Com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)&nbsp;rallied after experiencing a downturn earlier this month following President Donald Trump&#8217;s confirmation of a framework finalization for China trade deal.
Furthermore, the tariffs imposed by the Trump administration have led to a <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46111863/toy-prices-see-unprecedented-surge-as-trump-tariffs-take-a-toll-theres-just-no-escaping-china">surge in toy prices</a> in the U.S. The price of games and playground equipment saw a record 2.2% increase between April and May 2025, a rate significantly higher than the overall inflation rate, as close to 75% sellers in the U.S. import toys from China 
The potential trade agreement could alleviate these economic pressures, marking a significant step towards economic stability for both nations.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/markets/tech/25/06/46087590/trumps-made-in-america-phone-plan-is-backed-by-a-little-known-network-based-in-his-miami-condo-whose" target="_blank" rel="noreferrer noopener">Trump&#8217;s &#8216;Made in America&#8217; Phone Plan Is Backed By A Little-Known Network Based In His Miami Condo, Whose Website Still Says &#8216;What Is Lorem Ipsum?&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

BABA

BIDU

US-China Trade Deal Could Be Finalized Next Week, Says Harvard Scholar: 'They Are Going To Stabilize This'

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.
Shares of Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) fell sharply in today's pre-market trading after the company announced topline results from the IMPACT Phase 2b trial of Pemvidutide<a href="https://www.benzinga.com/quote/ALT/news"> in the treatment of MASH</a>.
Altimmune shares dipped 61.2% to $2.99 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) declined 14.9% to $2.0002 in pre-market trading as the company announced the pricing of public offering of its ordinary shares.</li>
<li>XCF Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFX#NASDAQ">SAFX</a>) fell 8.8% to $2.07 in pre-market trading after surging more than 32% on Wednesday.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) fell 7% to $39.38 in pre-market trading after the company priced its public offering of common stock.</li>
<li>Waldencast plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) fell 6.3% to $2.53 in pre-market trading.</li>
<li>Crescent Biopharma, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) shares fell 6.2% to $16.89 in pre-market trading. Stifel, on Wednesday, initiated coverage on the stock with a Buy rating and announced a price target of $28.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) fell 3.3% to $9.62 in pre-market trading.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) fell 2.7% to $5.03 in pre-market trading.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2"> Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

BTBT

CBIO

KTOS

SAFX

TIGR

WALD

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

WIIM

H.B. Fuller shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results and raised its FY2025 adjusted EPS guidance above estimates.

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/26025924/5405F09834F10234220980CBCBA52300_w5712h2895-900x600-1.png" alt="" class="wp-image-14912" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/26025924/5405F09834F10234220980CBCBA52300_w5712h2895-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/26025924/5405F09834F10234220980CBCBA52300_w5712h2895-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/26025924/5405F09834F10234220980CBCBA52300_w5712h2895-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The pharmaceutical services firm wants to expand production of peptides used in anti-obesity drugs, but it faces fierce competition and other business risks&nbsp;
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>The global market for developing and supplying pharmaceutical peptides is dominated by two players, leaving third-ranked Medtide with just a 1.5% slice</li>
<li>The company relies heavily on a handful of clients, leaving it exposed to any changes in business relationships </li>
</ul>
The booming global market for weight-loss drugs depends on an abundant supply of the active ingredients that help to suppress food cravings and ease digestion.
With big pharma brands cashing in on the insatiable demand for slimming drugs, lesser known firms in the supply chain are keen to grab some of the investor spotlight.&nbsp; Such is the premise for an IPO by a leading Chinese supplier of the peptides that serve as the base for weight management drugs.
Drug services provider&nbsp;Medtide&nbsp;(3880.HK) is looking to raise HK$514 million (410 million yuan or $65.48 million) in a listing on the Hong Kong stock market, with plans to invest the proceeds into expanding its peptide production capacity.
The&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0620/2025062000021.pdf">offer</a>&nbsp;opened last Friday, jointly sponsored by Morgan Stanley and CITIC Securities, with an indicative range of HK$28.40 to HK$30.60 per share. The issue price is to be determined on June 26.
The company plans to issue 16.80 million shares, with a subscription fee of HK$3090.85 per 100 shares, and has set aside a chunk of the offer for two cornerstone investors. Assuming a median price of HK$29.5 per share, CSPC Pharmaceutical&nbsp;(1093.HK) and Welight Capital will each take $5 million worth of stock, having subscribed for a total of 2.66 million shares or 15.8% of the overall issuance.
Medtide was founded in 2020 but a key subsidiary, Zhongtai Biochemical,started operating in 2001 as a peptide-focused supplier of wide-ranging services, from research and development to testing and manufacturing. The peptides are provided to customers as active pharmaceutical ingredients for combining with boosting agents to create the finished products.
Semaglutide and tirzepatide, the flagship weight-loss drugs sold by&nbsp;Novo Nordisk&nbsp;(NVO.US)and&nbsp;Eli Lilly&nbsp;(LLY.US), both contain peptides that mimic the action of GLP-1 hormones in controlling appetite and blood sugar.
The global peptide drug market is projected to grow from $89.5 billion in 2023 to $261.2 billion in 2032, a compound annual growth rate of 12.6%, according to research contained in the prospectus. With explosive demand threatening to outstrip supply, pharmaceutical giants are scrambling to lock in extra production capacity in partnership with service companies. Medtide has also strategically pivoted to the weight-loss market, partnering with seven clients on nine GLP-1 projects for injectable or oral drugs.
According to the report cited in the prospectus, the company is the world's third-biggest peptide-focused contract research, development and manufacturing organization (CRDMO), measured by 2023 revenue. However, the industry is top heavy, with the leading two companies controlling nearly 24% of the market while those ranked three to six have only around 1% each, the report said. Medtide's specific share was 1.5%.
<h4 class="wp-block-heading">Revenue reliance risks</h4>
While demand for weight-loss drugs is soaring off the charts, the company's earnings graph has not traced a steady climb over the last three years.
Turnover and profits dipped in 2023, a setback blamed on a handful of clients changing their drug development plans, highlighting the risks associated with small customer base.
Revenues came in at 351 million yuan in 2022, falling to 337 million yuan the following year before accelerating to 442 million yuan in 2024. Over the same timeframe, gross profits were 201 million yuan, 180 million yuan and 250 million yuan, while the company logged net profits of 53.98 million yuan, 48.91 million yuan and 59.17 million yuan.
The company explained in the prospectus that the actions by three clients in the U.S. and China caused 2023 revenue to drop 34 million yuan. Meanwhile, the 31% rise in 2024 revenues was driven by a single U.S. client focused on GLP-1 drug development.
As of last year, Medtide had 707 clients overall but relied on the top five for just over half of its revenue, with the single biggest customer contributing 26.8%. The small base leaves the company exposed to business shifts, as well as geopolitical risks. Overseas revenue accounts for nearly 79% of total revenue, with the U.S. market responsible for 55%, leaving Medtide vulnerable to trade disputes and U.S. tariff policies.
The company said 76.4% of the IPO proceeds would go towards building facilities for producing peptides and oligonucleotides in the United States and China. More specifically, 38.2% has been earmarked for the new Rocklin Site in California, which is due for completion in the first half of this year, boosting the firm's annual production capacity by between 100 kg and 300 kg. Another 9.5% of the funds would be spent on expanding the company's network of sales and post-sales service stations and 4.1% would go towards upping capacity in China.
Thanks to the GLP-1 craze, the company is heading for an IPO valuation of HK$4.18 billion based on the median issue price, with a potential price-to-earnings (P/E) ratio of 64 times compared with 18 times for industry leader&nbsp;WuXi AppTec&nbsp;(2359.HK; 603259.SH), which outperforms Medtide in both peptide drug capacity and earnings.
From here, Medtide's prospects could be tested by ferocious competition in the GLP-1 market, a highly concentrated customer base and any escalation of trade tensions.

Asia

IPOs

Opinion

Medtide Launches Hong Kong IPO to Boost Weight-loss Business

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer discretionary sector.
<h3 class="wp-block-heading">Jack in the Box Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 10.26%</li>
<li>Stifel analyst Chris O'Cull downgraded the stock from Buy to Hold and cut the price target from $32 to $20 on June 20, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Truist Securities analyst Jake Bartlett downgraded the stock from Buy to Hold and slashed the price target from $51 to $22 on May 27, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On June 24, Jack in the Box announced the return of Shannon McKinney as senior vice president, chief operating officer and new member of the executive leadership team.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626">JACK news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626"><img loading="lazy" decoding="async" width="900" height="816" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26043417/image-403.png" alt="" class="wp-image-962827" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26043417/image-403.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26043417/image-403-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26043417/image-403-768x696.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
<h3 class="wp-block-heading">Designer Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 8.77%</li>
<li>UBS analyst Jay Sole maintained a Neutral rating and lowered the price target from $3.5 to $3 on June 11, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating and slashed the price target from $5 to $4 on June 11, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On June 10, Designer Brands reported worse-than-expected first-quarter financial results and withdrew its FY25 guidance due to macroeconomic uncertainty.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626">latest DBI news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626"><img loading="lazy" decoding="async" width="912" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26043449/image-404.png" alt="" class="wp-image-962829" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26043449/image-404.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26043449/image-404-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26043449/image-404-768x706.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Monro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 8.16%</li>
<li>Wedbush analyst Seth Basham maintained an Outperform rating and cut the price target from $27 to $19 on April 1, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Stephens &amp; Co. analyst Rick Nelson initiated coverage on the stock with an Equal-Weight rating and a price target of $31 on Oct. 15, 2024. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On May 28, Monro reported a fourth-quarter revenue beat and approved a first-quarter cash dividend of 28 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest MNRO <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626"><img loading="lazy" decoding="async" width="907" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26044145/image-405.png" alt="" class="wp-image-962845" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26044145/image-405.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26044145/image-405-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26044145/image-405-768x704.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a></li>
</ul>
Photo via Shutterstock

Long Ideas

Dividends

JACK

MNRO

Wall Street's Most Accurate Analysts Weigh In On 3 Consumer Stocks With Over 8% Dividend Yields

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Catalyst Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Catalyst Pharmaceuticals posted better-than-expected quarterly earnings. &#8220;Catalyst&#8217;s exceptional first quarter performance underscores the continued strength of our commercial strategy and the growing demand for our differentiated therapies,&#8221; said Richard J. Daly, President and CEO of Catalyst. The company's stock fell around 13% over the past month and has a 52-week low of $14.75.</li>
<li>RSI Value: 27.5</li>
<li>CPRX Price Action: Shares of Catalyst Pharmaceuticals fell 2.4% to close at $21.54 on Wednesday.</li>
<li>Edge Stock Ratings: 81.89 Momentum score with Value at 60.40. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/cprx"><img loading="lazy" decoding="async" width="440" height="178" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034459/image-397.png" alt="" class="wp-image-962723" style="width:309px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034459/image-397.png 440w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034459/image-397-300x121.png 300w" sizes="(max-width: 440px) 100vw, 440px" /></a></figure>
<h3 class="wp-block-heading">AVITA Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 8, Avita Medical reported first-quarter financial results and missed its EPS and sales estimates. &#8220;We&#8217;ve transformed from a single-product, burn-only company into an integrated, multi-product platform positioned to lead in therapeutic acute wound care,&#8221; said Jim Corbett, Chief Executive Officer of AVITA Medical. &#8220;With the February rollout of RECELL GO mini and the nationwide launch of Cohealyx on April 1, our portfolio now addresses a U.S. market opportunity that has expanded from $455 million to more than $3.5 billion.&#8221; The company's stock fell around 21% over the past month and <a href="https://www.benzinga.com/quote/RCEL">has a 52-week low</a> of $4.71.</li>
<li>RSI Value: 24.2</li>
<li>RCEL Price Action: Shares of AVITA Medical fell 3.4% to close at $4.77 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626">RCEL stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626"><img loading="lazy" decoding="async" width="922" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034601/image-398.png" alt="" class="wp-image-962725" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034601/image-398.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034601/image-398-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034601/image-398-768x698.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Moleculin Biotech Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>)</h3>
<ul class="wp-block-list">
<li>On June 20, Moleculin Biotech announced a $5.9 million public offering of 16,080,000 shares and Series E warrants at $0.37 per share and accompanying warrant. The company's stock fell around 58% over the past five days and has a 52-week<a href="https://www.benzinga.com/quote/MBRX"> low of $0.25.</a></li>
<li>RSI Value: 21.4</li>
<li>MBRX Ltd Price Action: Shares of Moleculin Biotech fell 2.9% to close at $0.29 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626">MBRX share</a>s. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626"><img loading="lazy" decoding="async" width="885" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034652/image-400.png" alt="" class="wp-image-962727" style="width:558px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034652/image-400.png 885w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034652/image-400-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034652/image-400-768x726.png 768w" sizes="(max-width: 885px) 100vw, 885px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

CPRX

MBRX

RCEL

Top 3 Health Care Stocks You'll Regret Missing This Quarter

&nbsp;
On June 25, 2025, Actuate Therapeutics, Inc. (the "Company") entered into a securities purchase agreement (the "Securities Purchase Agreement") for a private placement (the "Private Placement") with certain institutional and accredited investors (each, a "Purchaser" and collectively, the "Purchasers").
&nbsp;
Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers an aggregate of (i) 666,497 shares (the "Shares") of the Company's common stock, par value $0.000001 per share (the "Common Stock"), at a purchase price of $7.00 per share, and (ii) warrants (the "Warrants") to purchase up to an aggregate of 666,497 shares of Common Stock (the "Warrant Shares") with an exercise price of $7.00 per Warrant. The Warrants will be exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the Milestone Date (as defined below) for additional proceeds to the Company of up to approximately $4.7 million if all Warrants are exercised in full. The "Milestone Date" is the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Company of its determination as to whether the Company may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data. Bios 2024 Co-Invest, LP, which is a current stockholder of the Company and, together with its affiliates following the closing of the Private Placement and including the Warrants and other rights to acquire Common Stock, is deemed to beneficially own approximately 49.9% of the Company's Common Stock, agreed to be a Purchaser of 71,428 shares and Warrants to purchase 71,428 shares in the Private Placement for an aggregate purchase price of $499,996. Dr. Aaron G.L. Fletcher, who is the Founder and President of Bios Research, is the Chairman of the Company's Board of Directors.
&nbsp;
The Private Placement is expected to close on or before June 30, 2025, subject to customary closing conditions. The Company anticipates the gross proceeds from the Private Placement to be approximately $4.7 million, before deducting fees and offering expenses. The Company intends to use the net proceeds from this proposed financing for working capital and general corporate purposes.

Biotech

General

ACTU

On June 25, 2025, Actuate Therapeutics Entered Into $4.7M Private Placement To Support Elraglusib Development And Corporate Growth

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) with a Buy and maintains $9 price target.

IVVD

D. Boral Capital Maintains Buy on Invivyd, Maintains $9 Price Target

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $4 price target.

Reiteration

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $4 Price Target

Kratos Defense & Security Solutions shares are trading lower after the company announced a $483.75 million public offering.

HC Wainwright &amp; Co. analyst Andrew Fein maintains Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Buy and raises the price target from $54 to $60.

KYMR

HC Wainwright & Co. Maintains Buy on Kymera Therapeutics, Raises Price Target to $60

Wells Fargo analyst Eva Fortea Verdejo initiates coverage on IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) with a Overweight rating and announces Price Target of $44.

Initiation

IDYA

Wells Fargo Initiates Coverage On IDEAYA Biosciences with Overweight Rating, Announces Price Target of $44

Cost Restructuring Initiatives
Veritone announced today that it has implemented certain cost and restructuring initiatives designed to further streamline the business and improve its financial condition following the completion of previously announced strategic transactions, accelerating its path to profitability. The recent cost reduction initiatives are expected to generate annualized savings of up to $10.0 million, of which over $7.5 million was executed in June 2025, and provide a clearer pathway to profitability as early as the second half of 2026.
Management expects the restructuring will result in a more efficient and effective operating structure to support both near- and longer-term growth initiatives, as well as continued innovation in AI software and solutions. Headcount remains the company's largest cost driver, followed by professional services, which have increased in recent periods due to higher transaction volume and integration efforts.
The Company expects to incur costs and expenses of between $0.5 million to $0.7 million as a result of these reductions primarily related to one-time severance, transition, and termination-related costs. Beyond these expected savings, Veritone will continue to manage its cost structure throughout 2025 to ensure necessary investments are timed with corresponding growth.

Management

VERI

Veritone Implements Cost Restructuring Plan To Accelerate Profitability By Late 2026; To Generate Savings Of Up To $10M

Acuity shares are trading higher after the company reported better-than-expected Q3 financial results.

Health Care

NRXP

NRx Pharmaceuticals Subsidiary, HOPE Therapeutics, Signs Binding LOI To Purchase 49% Interest In Cohen and Associates Neuropsychiatry Clinic; Terms Not Disclosed

NIKE, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) will release earnings results for the fourth quarter, after the <a href="https://www.benzinga.com/quote/NKE/earnings">closing bell on Thursday, June 26</a>.
Analysts expect the Beaverton, Oregon-based company to report quarterly earnings at 13 cents per share. That&#8217;s down from 99 cents per share in the year-ago period. Nike projects to report quarterly revenue at $10.72 billion, compared to $12.61 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The company has beaten analyst estimates for revenue in two straight quarters and beaten estimates in six of the last 10 quarters overall.
With the recent buzz around Nike, some investors may be eyeing potential gains from the company's dividends too. As of now, Nike offers an annual dividend yield of 2.63%, which is a quarterly dividend amount of 40 cents per share ($1.60 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $228,113 or around 3,750 shares. For a more modest $100 per month or $1,200 per year, you would need $45,623 or around 750 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.60 in this case). So, $6,000 / $1.60 = 3,750 ($500 per month), and $1,200 / $1.60 = 750 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
NKE Price Action: Shares of Nike fell 1% to close at $60.83 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Earnings

How To Earn $500 A Month From Nike Stock Ahead Of Q4 Earnings

Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225
Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer
FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Nusano, a physics company transforming the production of radioisotopes, today announced the signing of a multi-year supply agreement in which Nusano will provide Cellectar with iodine-125 (I-125) and actinium-225 (Ac-225) for its clinical studies and future commercial needs.

CLRB

Cellectar Biosciences And Nusano Sign Multi-Year Supply Agreement; Nusano To Provide Cellectar With Iodine-125 And Actinium-225 For Clinical Studies And Future Commercial Needs

Press Releases

Nebius Academy and Stevens Institute of Technology Launch Lab to Explore How AI Can Advance Math Research and Education

Nebius to Offer NVIDIA Blackwell Ultra-Powered Instances

DDN and Nebius Collaborate to Power Next-Generation AI Infrastructure for Seamless Enterprise Adoption

Nebius Welcomes Bezos Expeditions as Lead Investor in AI Data Business Toloka

Nebius Group N.V. Announces First Quarter 2025 Financial Results

Marc Boroditsky Joins Nebius as Chief Revenue Officer

Nebius participates in ClickHouse Series C; crystallizes value of asset to fund hypergrowth of core AI infrastructure business

Nebius Group announces private placement of $1 billion in aggregate principal amount of convertible notes

WEKA and Nebius Partner to Catalyze AI Innovation With Ultra-High-Performance Cloud Infrastructure Solution

Nebius delivers first NVIDIA Blackwell general availability in Europe; brings NVIDIA AI Enterprise to Nebius AI Cloud

NBIS

DA Davidson

BWS Financial

Northland Capital Markets

Comments

Nebius Group

Actualités

Dernières nouvelles pour Nebius Group (NASDAQ:NBIS) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL